Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo (Nasdaq: MASI) reported third quarter 2025 continuing-operations results on November 4, 2025 with GAAP revenue $371.5M (up 8.2% reported) and non-GAAP EPS $1.32 (up 38% year-over-year). Operating margin improved by 450 basis points. Management closed the sale of Sound United and used net proceeds for share repurchases and expanded a strategic partnership with Philips. Updated 2025 non-GAAP guidance: revenue $1,510–1,530M (+8.5% to 10.0% constant currency); EPS $5.62–$5.79 excluding new tariffs and $5.40–$5.55 including estimated tariff impact. Investor Day scheduled for Dec 3, 2025.
Masimo (NASDAQ: MASI) will release third quarter 2025 financial results for the period ended September 27, 2025 after market close on Tuesday, November 4, 2025. The company will host a conference call and webcast the same day at 1:30 p.m. PT / 4:30 p.m. ET, led by CEO Katie Szyman and CFO Micah Young.
Participants must register to receive the dial-in number and registrant ID; registrants will receive email reminders. A replay of the webcast and conference call will be available shortly after the call and archived on the company website.
Masimo (NASDAQ: MASI) will host an Investor Day on Wednesday, December 3, 2025 at 9:00am PT. Presentations by members of the Executive Leadership Team will cover the company’s business overview, market opportunities, innovation pipeline, commercial growth strategy, and long-term financial outlook.
Investors can join via live webcast on the Investor Relations site under Events and Presentations. A replay and related slide presentations will be posted on the company website after the event. In-person attendance is by invitation and requires registration.
Masimo (NASDAQ: MASI) reported results from a feasibility analysis of the INSPIRE trial showing Masimo SET® pulse oximetry performed accurately across a range of skin tones in critically ill adult ICU patients. In the first 50 enrolled patients (80 paired SpO2–SaO2 readings), overall ARMS was 1.47% (below the FDA 1.5% spec and outperforming the 3% industry standard), median bias was -0.6%, and zero occult hypoxemic events were observed. The study used a validated colorimeter to classify skin pigmentation and included 39% of pairs collected during low perfusion. Data collection for the planned 502-patient INSPIRE trial is ongoing.
Masimo (NASDAQ: MASI) has successfully completed the sale of its Sound United consumer audio business to HARMAN International, a Samsung Electronics subsidiary. CEO Katie Szyman emphasized that this divestiture represents a strategic milestone in focusing on their core professional healthcare business.
The company plans to use the proceeds primarily for share repurchases. This move is expected to help Masimo enhance its focus on healthcare operations, accelerate growth, and improve profit margins. Centerview Partners LLC and Morgan Stanley & Co. LLC acted as financial advisors, while Sullivan & Cromwell LLP served as legal advisor for the transaction.
HARMAN International, a Samsung Electronics subsidiary, has completed the acquisition of Sound United from Masimo Corporation (NASDAQ: MASI). The acquisition integrates Sound United's premium audio brands including Bowers & Wilkins, Denon, Marantz, Definitive Technology, Polk Audio, HEOS, Classé, and Boston Acoustics into HARMAN's portfolio.
Sound United will operate as a standalone Strategic Business Unit (SBU) within HARMAN's Lifestyle Division, preserving each brand's heritage while leveraging HARMAN's global resources. The strategic integration aims to expand HARMAN's core audio business across key product categories including home audio, electronics, headphones, and car audio, positioning HARMAN as a comprehensive audio industry leader.
Masimo (NASDAQ: MASI) announced significant findings from a Dartmouth-Hitchcock Medical Center study showing that continuous patient monitoring using Masimo SET® and Patient SafetyNet™ technologies not only improves patient outcomes but also generates substantial cost savings.
The study, analyzing 31,993 patients over 3.5 years, revealed that avoiding patient rescue events saved approximately $5,500 per patient, while preventing transfer events saved about $10,700 per patient. For a 200-bed facility using Masimo monitoring, each 10% reduction in rescues and transfers projected annual savings of $350,000 and $409,000 respectively.
The research demonstrated that 92.7% of monitored patients had uncomplicated stays, generating an average operating gain of $2,016 per patient, while complicated cases resulted in significant losses.
Masimo (NASDAQ: MASI) has announced a significant multi-year renewal and expansion of its strategic partnership with Royal Philips (NYSE: PHG) through 2026 and beyond. The expanded collaboration will accelerate the integration of Masimo's monitoring technologies, including SET® pulse oximetry, into Philips' multi-parameter patient monitors.
The partnership includes integration of Radius PPG® with Masimo-board equipped Philips monitors and the development of next-generation wearable solutions. The companies will jointly develop and promote AI-based monitoring technologies. Additional Masimo technologies available on Philips devices include SpHb®, O3® regional oximetry, SedLine® brain function monitoring, and NomoLine® capnography.
Masimo (NASDAQ: MASI) announced its participation in the upcoming Wells Fargo Healthcare Conference. The company's management will present on Thursday, September 4, 2025, at 1:30 p.m. Eastern time. Investors can access the presentation through a live webcast on Masimo's website, with a replay available after the event.
Masimo (NASDAQ: MASI) has received FDA 510(k) clearance for expanded indications of its O3® Regional Oximetry's delta hemoglobin parameters (ΔcHb, ΔHHb, and ΔO2Hb). The expanded clearance now covers both cerebral and somatic applications across all patient populations, including pediatric and neonatal patients.
The O3 system, available on Masimo's Root® platform, uses near-infrared spectroscopy (NIRS) to monitor regional oxygen saturation (rSO2). The delta hemoglobin parameters provide crucial insights into why a patient's rSO2 is changing by tracking changes in total hemoglobin, deoxygenated hemoglobin, and oxygenated hemoglobin. Clinical studies, including a 2024 randomized controlled trial, have demonstrated improved maintenance of cerebral physiology in elderly patients using these parameters.
The technology offers both trending and absolute accuracy specifications, with ARMS accuracy of 4% for cerebral monitoring in adults and 5% for pediatric cerebral and adult non-cerebral applications.